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Next-generation sequencing (NGS) studies have identified large numbers of genetic
variants that are predicted to alter miRNA–mRNA interactions. We developed a
novel high-throughput bioassay, PASSPORT-seq, that can functionally test in parallel
100s of these variants in miRNA binding sites (mirSNPs). The results are highly
reproducible across both technical and biological replicates. The utility of the bioassay
was demonstrated by testing 100 mirSNPs in HEK293, HepG2, and HeLa cells. The
results of several of the variants were validated in all three cell lines using traditional
individual luciferase assays. Fifty-five mirSNPs were functional in at least one of three
cell lines (FDR ≤ 0.05); 11, 36, and 27 of them were functional in HEK293, HepG2, and
HeLa cells, respectively. Only four of the variants were functional in all three cell lines,
which demonstrates the cell-type specific effects of mirSNPs and the importance of
testing the mirSNPs in multiple cell lines. Using PASSPORT-seq, we functionally tested
111 variants in the 3′ UTR of 17 pharmacogenes that are predicted to alter miRNA
regulation. Thirty-three of the variants tested were functional in at least one cell line.
Keywords: SNP, functional testing, genetic variants, miRNA, high-throughput screening assays, 3′ UTR
INTRODUCTION
Large scale sequencing studies and genome-wide association studies (GWASs) have identified
1000s of genotype–phenotype associations (Welter et al., 2014). Some of the phenotype-associated
variants alter gene function and many of them are in linkage disequilibrium with the functional
variants. The functional impacts of variants can be predicted using bioinformatic algorithms,
but the in silico predictions are often incorrect and need experimental validation. While there
are several experimental methods to functionally test variants, most do not have the capacity to
simultaneously test the large number of variants.
Nearly 90% of genetic variants associated with phenotypes have been described to be located
in non-coding regions such as the untranslated regions (UTRs) (Hindorff et al., 2009). Variants,
including single nucleotide polymorphisms (SNPs) within non-coding regions, can impact gene
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expression in several ways; one example is by altering the
interaction between mRNAs and micro-RNAs (miRNAs).
Polymorphisms within miRNA-binding sites have been
implicated in diseases such as cancer (Pelletier and Weidhaas,
2010; Iuliano et al., 2013), Alzheimer’s disease (Liu et al., 2017),
and diabetes (Elek et al., 2015).
miRNAs are 21–23 nucleotide long RNAs that post-
transcriptionally silence genes or reduce their expression levels
by complementarily binding to target sites within mRNAs. More
than 29,000 human mRNAs are collectively targeted by are over
2500 miRNAs (Kozomara and Griffiths-Jones, 2014). Several
different miRNA binding sites may be present on one mRNA
and many contain genetic variations. To date, over 400,000 SNPs
have been identified in miRNA binding sites (Liu et al., 2012).
Interestingly, only about 32,000 have a minor allele frequency
greater than 1% classifying most of them as rare variants (Liu
et al., 2012). Thus, tests to identify functional SNPs affecting
miRNA binding, here referred to as mirSNPs, will involve
screening a large number of variants.
Testing these large number of mirSNPs using GWAS requires
statistical correction for multiple testing, such as the Bonferroni
correction. The low minor allele frequency of many causal
variants, and routine multiple comparisons corrections make it
very difficult, or impossible, to statistically identify functionally
relevant variants in genome-wide studies. Consequently, in
GWAS, impractically large numbers of subjects from diverse
populations would be required to identify rare functional
variants that are statistically significant. Lowering the statistical
threshold or not correcting for multiple comparisons increases
the sensitivity to detect rare variant associations, but results
in the detection of many false positives signals. Despite some
technical challenges, high-throughput in vitro approaches have
been implemented that are specific to variants in certain non-
coding regions, such as splice-junctions (Soemedi et al., 2014)
and promoters (Kwasnieski et al., 2012; Melnikov et al., 2012).
However, we are not aware of any high-throughput assays
available to functionally test variants in miRNA binding sites (Ipe
et al., 2017).
We developed PASSPORT-seq (parallel assessment of
polymorphisms in miRNA target-sites by sequencing), a high-
throughput bioassay that involves pooled synthesis, parallel
cloning and single-well transfection followed by next-generation
sequencing (NGS) to functionally test 100s of mirSNPs at once.
This assay produced results that are reproducible and consistent
with luciferase reporter assays, a gold-standard platform widely
used to assess gene expression in vitro. We also demonstrate
the application of this assay to test 111 genetic variants that are
predicted to alter miRNA regulation of 17 pharmacogenes.
MATERIALS AND METHODS
Selection of mirSNPs
RNA samples from thirty human livers were sequenced using
SOLiD R© technology (Thermo Fisher Scientific, Waltham, MA,
United States). SNPs in the 3′ UTRs were identified (O’Leary
et al., 2016) and an 8-base pair region on either side of the
reference and variant alleles was analyzed using TargetScan
(Lewis et al., 2005) to identify SNPs that were in miRNA seed
binding regions. SNPs that altered the predicted miRNA seed
binding sites were considered for further analysis. For assay
development, 84 SNPs that were associated with allele-specific
expression in the sequencing dataset were selected. A flowchart
representing the selection process of the 84 test mirSNPs is shown
in Supplementary Figure 1. In addition, we selected 16 mirSNPs
from the SomamiR database (Bhattacharya et al., 2013) that have
been linked with cancer. The list of 100 SNPs used for assay
development are listed in Supplementary Table 1. Similarly, 111
mirSNPs located in the 3′ UTR regions of 17 pharmacogenes-
the core absorption, distribution, metabolism, and excretion
(ADME) genes1, PXR, CAR, and HNF4α which showed allele
specific expression in the sequencing dataset were selected to
demonstrate the application of the assay. The list of these 111
SNPs are listed in Supplementary Table 4. The RNA analysis and
genotyping was approved by the Indiana University Institutional
Review Board.
Test Sequence Design
The 5′ and 3′ flanking regions for each SNP were obtained
from dbSNP. A 32-nucleotide region which contained either the
variant or reference nucleotide flanked by nine nucleotides on
the 3′ end and 22 nucleotides on the 5′ end was selected as the
test sequence. Two-hundred such regions (100 reference and 100
variant) were selected to test 100 SNPs. Universal primer binding
regions were added on the 5′ (GTAATTCTAGGAGCTC) and
3′ (CGTTCTAGAGTCGGG) end of each test region. The final
test fragment was 63 nucleotides in length (see Supplementary
Figure 2). The 200 test fragments were commercially synthesized
as pooled single-stranded DNA oligonucleotides (Oligomix R©,
LC Sciences, Houston, TX, United States). The pool contained
10–50 attomoles of each sequence. The oligonucleotides were
synthesized as single-stranded DNA and was diluted 1:5. One µL
of the diluted Oligomix R© was amplified in a 50 µL PCR reaction
using 0.3 µM universal primers and 25 µL 2X CloneAmpTM HiFi
PCR premix (Takara, Mountain View, CA, United States). PCR
conditions used were: 98◦C (10 s), 53◦C (5 s), and 72◦C (5 s) for
35 cycles.
Seven SNPs were also tested in individual luciferase assays
using 63-nucleotide long single stranded oligonucleotides that
were individually synthesized (reference and variant); (Integrated
DNA Technologies, Coralville, IA, United States), made double
stranded as described for pooled oligonucleotides, and cloned
into the pIS-0 plasmid.
Plasmid Library Preparation
The pIS-0 vector (plasmid 12178; Addgene, Cambridge,
MA, United States) (Yekta et al., 2004) (see Supplementary
Figure 3) was linearized with SacI-HF R© and BmtI-HF R©
restriction endonucleases (New England Biolabs, Ipswich,
MA, United States) and purified using QIAquick R© PCR spin
columns (Qiagen, Germantown, MD, United States). Plasmid
assembly was performed using 40 ng of linearized plasmid and
1http://www.pharmaadme.org/joomla/
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2 µL of unpurified PCR product containing double-stranded
test oligonucleotides using the NEBuilder R© HiFi DNA assembly
kit (NEB, Ipswich, MA, United States) per manufacturer’s
instructions. The universal primers used to amplify the test-
oligonucleotide pool also served as the flanking homology
regions for the NEBuilder R© assembly. Two µL of the NEBuilder R©
assembly product were transformed into 60 µL chemically
competent E. coli (transformation efficiency > 5 × 108 cfu/µg)
(Takara, Mountain View, CA, United States) and plated on
six standard 100 mm LB-agar plates containing 100 µg/ml
ampicillin. After overnight incubation, all colonies were
dislodged from the plates by adding 2 ml LB-broth containing
100 µg/ml ampicillin and agitation using 10–20 ColiRollersTM
glass beads (EMD Millipore, Billerica, MA, United States). The
colonies harvested from the six plates in LB-broth were pooled
together. The liquid culture was incubated at 37◦C for 5 h after
which plasmids were isolated using 10 QIAprep R© Spin miniprep
columns (Qiagen, Germantown, MD, United States) as per
manufacturer’s instructions. Column elutions were combined
to create the plasmid library that was used for downstream
experiments. The plasmid DNA concentration was determined
using a Quant-iTTM DNA Broad Range kit (Thermo Fisher
Scientific, Waltham, MA, United States).
Sanger Sequencing
To determine the representation of the test constructs in the
plasmid library, 28 individual colonies were grown in LB-broth
containing 100 µg/ml ampicillin. Plasmids were isolated using
QIAprep R© Spin miniprep columns (Qiagen, Germantown, MD,
United States) as per manufacturer’s instructions and Sanger
sequenced using a primer (GTGGTTTGTCCAAACTCATC)
near the test insert (ACGT, Inc., Wheeling, IL, United States).
Transfection of Cells in Culture
The plasmid library was used to transfect three different human
cell lines: HEK293 (embryonic kidney), HepG2 (liver carcinoma),
and HeLa (cervical cancer). Cells were seeded at a density of
0.9 × 105 cells per well into 24- well plates. The cells were
transfected 24 h after plating with 500 ng/well of the pIS-
0 plasmids. Ten ng of pGL4.74, a Renilla luciferase reporter
plasmid, was added to each well as a transfection control.
Transfection was performed using 50 µL transfection-mix in
Opti-MEM R© (Life Technologies, Carlsbad, CA, United States)
containing 1.5 µL Lipofectamine R© 3000 (Life Technologies,
Carlsbad, CA, United States) per the manufacturer’s instructions.
Opti-MEM R© and culture media were used with no antibiotics.
RNA Isolation and cDNA Synthesis
Transfected cells were incubated for 48 h, lysed in situ and total
RNA isolated using a RNeasy R© purification kit with the optional
DNase treatment (Qiagen, Germantown, MD, United States).
RNA was quantified using the Quant-iTTM RNA Broad Range
kit (Thermo Fisher Scientific, Waltham, MA, United States)
and cDNA synthesized from 800 ng of total RNA using the
QuantiTect R© Reverse Transcription kit (Qiagen, Germantown,
MD, United States).
Molecular Barcoding
Using the cDNAs from the transfected cells, the miRNA
binding sites within the 3′ UTR of the luciferase genes were
amplified in 50 µL PCR reactions using 0.3 µM flanking
universal primer sand 25 µL 2X CloneAmpTM HiFi PCR
premix (Takara, Mountain View, CA, United States). In a
separate reaction for each sample, 2 µL of cDNA and
1 pg of the input plasmid pool was used as PCR template.
PCR conditions used were: 98◦C (10 s), 54◦C (5 s), and
72◦C (5 s) for 25 cycles. A 6-nucleotide unique molecular
barcode was added to the 5′-end of both the forward and
reverse primer (see Supplementary Table 2). The input pools
(n = 4 replicates) and the five biological replicates in the
three different cell lines were each ‘barcoded’ by a unique
pair of sequences. The barcoded PCR products were purified
using a MinElute R© PCR Purification kit (Qiagen, Germantown,
MD, United States). The barcoded libraries were combined in
equimolar concentrations to create a sequencing pool with 19
different molecular barcodes. A schematic representation of the
steps involved in creating this sequencing pool is shown in
Figure 1.
Next-Generation Sequencing
The pooled PCR products were sequenced using a modified
protocol for the Ion ProtonTM system (Thermo Fisher Scientific,
Waltham, MA, United States). Briefly, the sequencing library was
created by end-polishing the barcoded PCR products, followed
by adapter ligation and amplification. The resulting library was
quantified and its quality accessed with the Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA, United States). Eight
microliters of the 100 pM library were then applied to Ion
Sphere Particles to prepare the sequencing template. The
template was amplified using Ion OneTouch 2. The Ion Sphere
Particles with the amplified template were loaded onto an
IonPI R© chip and sequenced on the Ion Proton system per
manufacturer’s instructions. Approximately, 41 million reads
were generated from each sequencing run. Raw reads were
generated as fastq files for bioinformatic analysis. Sequencing
data has been made publicly available through GEO (Accession
No. GSE111845).
Bioinformatic Analysis
The raw reads were aligned to the reference library containing
the 200 test sequences (TMAP- Ion Torrent Suite R©, Thermo
Fisher Scientific, Waltham, MA, United States). The reads that
aligned to the reference library were filtered to retain reads
with a mapping quality greater than 20 and further filtered
to include only those sequences with perfect barcodes at both
ends.
Differential expression analysis compared the expression of
each variant to its respective reference allele for all SNPs. To
account for differences in the concentrations of the variant and
reference plasmids that were used for the transfections, a plasmid
input correction factor for each target site was calculated as the
average of the number of reads from the variant plasmid divided
by the number of reads from the reference plasmid across four
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FIGURE 1 | Workflow of the PASSPORT-seq bioassay. (A) 100 Reference and variant miRNA binding regions each with the same 15–20 bp flanking sequence was
synthesized as an oligonucleotide pool. (B) Using the flanking universal sequences, the oligonucleotide pool was amplified and made double stranded by PCR.
pIS-0 plasmid was linearized by restriction enzymes. (C) The double stranded oligonucleotides were inserted into the linear plasmid using the NEBuilderTM gene
assembly system. (D) Chemically competent bacteria were transformed with the plasmid pool containing the test miRNA binding regions. Transformed bacteria were
plated on four plates. (E) All colonies from the plates were harvested, combined and scaled up in liquid culture. Plasmids were isolated from the liquid culture.
(F) Three cell lines were transfected with the plasmid pool and incubated for 48 h after which cDNA was prepared from total RNA. (G) miRNA binding regions were
amplified using universal primers that were uniquely barcoded for replicates within cell lines and for the input plasmid pool. (H) The barcoded PCR products were
combined to form the sequencing pool.
replicates of the plasmids. The reads from the variant alleles
for all biological replicates were divided by the input correction
factor. The corrected read counts were fit into a generalized linear
model using EdgeR (Robinson et al., 2010) assuming a negative
binomial distribution. Biological replicates and the genotype
were used as covariates. p-Values and log2 fold-change of the
variant alleles compared to the respective reference alleles were
derived using a likelihood ratio test on the genotype variable in
the generalized linear model. The p-values were corrected for a
false discovery rate (FDR) using the Benjamini and Hochberg
algorithm (Benjamini and Hochberg, 1995). The EdgeR script can
be found in Supplementary File 1.
The two sequencing runs, each with five biological replicates,
were analyzed together by fitting the number of reads for 10
pairs of variant and reference alleles (five from each experiment).
The different sequencing runs were included as an additional
covariate. The statistical analysis was performed as described
above.
Luciferase Reporter Assay
Genetic variants, including mirSNPs have been functionally
tested using a reporter plasmid such as the pIS-0 vector (Yekta
et al., 2004; Adams et al., 2007; Ramamoorthy et al., 2012). This
plasmid contains the firefly luciferase gene whose expression
can be quantified either by qPCR or by the luciferase reporter
assay. The reference or variant allele version of the predicted
miRNA binding sites were cloned into the 3′ UTR of the
luciferase gene within the plasmid. The plasmids were then
transfected into cells as described above. Forty-eight hours
after transfection, cells were lysed in situ and Dual-Luciferase R©
assays were performed per manufacturer’s instructions (Promega,
Madison, WI, United States). The luciferase reporter activity
was measured using a 96-well plate-reader (BioTek, Winooski,
VT, United States). The firefly luciferase activity was normalized
to that of Renilla luciferase in each well. The ratio of the
normalized luciferase activity from the variant and reference
plasmid provides a relative measure of SNP-mediated differential
mRNA expression.
RESULTS
The traditional luciferase reporter assay is useful in low-
throughput experiments, but is not a practical and cost-effective
method to test the 1000s of mirSNPs identified at a genome-
wide scale. As a novel approach, we modified the luciferase
reporter assay to develop PASSPORT-seq that can functionally
test 100s of mirSNPs in parallel. Since one of the mechanisms
of miRNA regulation is by degrading mRNA, this assay was
specifically designed to evaluate the impact of genetic variation
in miRNA binding sites on mRNA expression. We recognize
that miRNAs also alter mRNA translation, however measuring
protein levels does not distinguish between the impact on mRNA
vs. translation and thus would not provide the same mechanistic
insights. We identified 100 variants in predicted seed sequences of
miRNA binding sites, and cloned the binding sites into the pIS-0
luciferase plasmid; each contained either the reference or variant
nucleotide of 100 selected mirSNPs. The pool of the resulting
200 plasmids was then transfected into three cell lines and the
luciferase gene expression measured by NGS. A difference in
mRNA expression between the reference and the variant plasmids
indicated a functional mirSNP.
Cloning Efficiency and Plasmid
Representation
To test the efficiency of the parallel cloning, plasmids from
28 individual colonies were isolated and the sequence of the
inserts were determined by Sanger sequencing. Out of the 28
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colonies, 25 contained inserts without errors; of those, 24 were
unique sequences suggesting that the cloning efficiency was
high and there was negligible sequence-bias in the plasmid
pool. Furthermore, as described below, all 200 sequences were
observed in the NGS of the entire pool.
Reproducibility Across Biological
Replicates
To test the reproducibility of the PASSPORT-seq bioassay, we
first performed the assay with five biological replicates in each
of the three cell lines and compared the number of reads from
two of the five biological replicates. The input plasmid libraries
had representation of all 100 allelic pairs. The R2 value for the
comparison of sets of two of the five input normalized-biological
replicates within the same sequencing run was between 0.68 and
0.98 (p < 0.05; Supplementary Figure 4) demonstrating highly
reproducible results within a run.
Reproducibility Across Runs
Next, we repeated the PASSPORT-seq assay again with another
five biological replicates in each of the three cell lines to validate
the observed results. A separate cDNA and sequencing library
was created for the experiments. A strong correlation (R2 = 0.98;
p< 0.05) was observed in the results from the plasmid pool from
the first sequencing run and those from the second sequencing
run (see Supplementary Figure 5). There was a high correlation
(R2 = 0.74; p< 0.05) in the results between the first and second set
of biological replicates (Figure 2 and Supplementary Figure 6).
This strong correlation between results of the first sequencing run
with those of the second sequencing run across the three cell lines
demonstrates the high reproducibility of the observed results.
Identification of Functional mirSNPs
Of the 100 mirSNPs tested, 69 showed statistically significant
(p < 0.05) differences in expression between the variant and its
respective reference allele in at least one cell line (Figure 2B).
FIGURE 3 | Functional SNPs in the cell lines. Venn diagram (Micallef and
Rodgers, 2014) showing the number of unique and overlapping functional
SNPs that were identified by the PASSPORT-seq assay in the three cell lines.
Total number of functional SNPs identified in each cell line is indicated in
parenthesis.
In HEK293, HepG2, and HeLa a significant effect was seen
in 27, 44, and 39 mirSNPs, respectively (see Supplementary
Figure 7). Due to the large number mirSNPs tested, the results
were corrected using the Benjamini and Hochberg procedure
across cell lines. This conservative threshold (FDR ≤ 0.05) was
met by 55 mirSNPs in at least one cell line with 11, 36, and 27
in HEK293, HepG2, and HeLa cells, respectively. Because these
variants were informatically predicted to be functional, this may
be an overly conservative statistical correction. The effect of the
mirSNPs was cell line- specific; four SNPs were functional across
all three cell lines, while others were functional in either two cell
lines or unique to one cell line (Figure 3).
Validation With Traditional Luciferase
Assays
Twenty-one of the results were validated using traditional
individual luciferase transfection experiments. The variant and
FIGURE 2 | Validation of the PASSPORT-seq assay. (A) Correlation between the percent-change of variant alleles compared to respective reference alleles observed
in the experimental and validation PASSPORT-seq runs. Each run contained five biological replicates tested in three cell lines. The graph includes combined average
data from all three cell lines. (B) Functional mirSNPs identified by the PASSPORT-seq assay. For each SNP, the observed percent change in the expression of the
variant allele compared to the respective reference allele in predicted miRNA binding site was calculated Statistically significant changes after correction for multiple
testing using Benjamini and Hochberg algorithm are indicated by colored boxes. Blue boxes indicate a reduction in the variant allele expression and Orange boxes
indicate increased expression. Results from the experimental and validation runs are shown. Additionally, results of the analysis with merged data from experimental
and validation runs are also represented.
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reference allele binding sites of the selected mirSNPs were
individually cloned into the 3′ UTR of the luciferase gene within
the pIS-0 plasmid and transfected into HEK293, HepG2, and
HeLa cells. This included seven of the miRNA target sequences,
each with reference and variant sequences, tested in three cell
lines for a total of 21 validations. Within each cell line, the
luciferase activity in the cells transfected with the reference
plasmid was compared to the activity in the cells transfected
with the variant plasmids. The effect of the variants in these
individual luciferase assays were compared with the results
from the PASSPORT-seq assay (Figure 4). In 17 of the 21
comparisons, the statistical significance of the results and the
direction of the effect of the variant matched the PASSPORT-
seq results (Supplementary Figure 8 and Supplementary Table 3).
In an additional two comparisons (rs3134615 in HeLa and
HEK293 cells), the results were statistically significant in one
assay, but not the other, but the direction and magnitude of
effect of the variant in the PASSPORT-seq was similar to the
luciferase assay in both cell lines (Supplementary Figure 8).
Thus, the results were very similar in 19 of the 21 comparisons
(>90%).
Application of PASSPORT-seq
To demonstrate the utility of this assay, mirSNPs predicted to
alter miRNA regulation of 17 pharmacogenes were selected for
functional testing from the RNA-seq dataset described earlier.
These variants were functionally tested using the PASSPORT-
seq assay in HeLa, HepG2, HEK293, and HepaRG (hepatic cells
that retain characteristics of primary human hepatocytes) cells.
Out of the 111 genetic variants tested, the effect of 33 variants
were statistically significant in at least one cell line, including
6, 13, 12, and 27 in HeLa, HepG2, HEK293, and HepaRG
cells, respectively (Figure 5 and Supplementary Table 4). The
effects of several mirSNPs were shown to be cell line-specific.
Only four mirSNPs had significant effects in all the four cell
lines (Figure 6). The effect of a genetic variant (rs12979270),
located in the 3′ UTR of the pharmacogene- CYP2B6, was shown
to be statistically significant in HepaRG cells. A recent study
shows that this variant, could explain part of the interindividual
variability seen in the activity of this critical pharmacogene
(Burgess et al., 2017). These results demonstrate the potential
of this assay to identify clinically relevant functional genetic
variants.
FIGURE 4 | Comparison of the results from the PASSPORT-seq assay with those from the luciferase reporter assay. Correlation between results of the
PASSPORT-seq assay (P-seq) and the luciferase reporter assay (Luc); in (A) HEK293, (B) HepG2 cells, and (C) HeLa cells. The results of the two assays are
represented as the percent-change observed in the variant allele compared to its respective reference allele. Tables show the magnitude of change observed in each
sample using the two different assays: < 5% = 0, ≥ 5 to < 10% = –/+, ≥ 10 to < 15% = −−/++, ≥ 15% = −−/+++. ‘–’ indicate decreased expression and ‘+’
indicate increased expression. The rs numbers of the SNPs can be identified based on the table.
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FIGURE 5 | Functional mirSNPs in pharmacogenes identified by the PASSPORT-seq assay. For each SNP, the observed percent change in the expression of the
variant allele compared to the respective reference allele in predicted miRNA binding site was calculated. Statistically significant changes after correction for multiple
testing using Benjamini and Hochberg algorithm are indicated by colored boxes. Blue boxes indicate a reduction in the variant allele expression and Orange boxes
indicate increased expression.
DISCUSSION
We developed PASSPORT-seq to screen 100s of SNPs that are
predicted to alter miRNA–mRNA interactions. The availability
of pooled oligonucleotide synthesis and the NEBuilder R© gene
assembly system have made this assay possible. Our assay
builds and substantially improves the technologies that have
had only limited success (Reid et al., 2009). For example,
in previous high-throughput splicing assays, short inserts
were underrepresented during the library construction using
traditional cloning methods (Chen and Chasin, 1994; Ke
et al., 2011; Soemedi et al., 2014). In contrast, our library
had representation of all allele pairs. This may be explained
by the cloning method we utilized, i.e., the NEBuilder R©
gene assembly system that produces covalently closed circular
plasmids as opposed to traditional cloning methods, which
yield a nicked-relaxed plasmid topology. This change in
topology may result in a more efficient plasmid uptake by
chemically competent bacteria (Hanahan, 1983; Xie et al., 1992;
Kobori and Nojima, 1993). Better transformation efficiency
increases the probability of both the variant and reference
plasmids being represented in the resulting pool, which is a
critical prerequisite for studying the allele-specific activity of
miRNAs.
The activity of miRNAs on target sequences have been
studied using reporter assays where the target sites of interest
are cloned into the 3′ UTR of a reporter gene followed by
quantification of the reporter activity. Typical reporter assays
also overexpress the miRNAs that are predicted to regulate the
target site (Cloonan et al., 2008; Loya et al., 2009; Baccarini and
Brown, 2010). Such overexpression, however, may not provide
a physiological context to the miRNA–mRNA interaction. For
example, high miRNA expression levels may force interactions
with mRNAs that do not normally occur. They can also compete
with the miRNA processing machinery or binding sites and
alter normal miRNA function. In contrast, our assay was
performed in the endogenous miRNA expression background,
which provides a more physiologically relevant context of the
results. In addition, we used multiple different cell lines to
allow parallel testing to identify cell line-specific effects of the
mirSNPs.
miRNAs regulate gene expression by either degrading the
target mRNAs or by binding to mRNAs and blocking translation.
Traditional luciferase assays test the effect of miRNA by
measuring differences in its target protein activity. However, the
differences in protein activity due to mRNA degradation and
those from translational blockage will be indistinguishable using
FIGURE 6 | Cell line-specificity of functional mirSNPs in pharmacogenes.
Venn diagram (Bardou et al., 2014) showing the number of unique and
overlapping functional mirSNPs in the four cell lines tested.
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luciferase activity assays. The PASSPORT-seq assay provides
additional evidence of the mechanism underlying the effect
of the variant by specifically detecting only the changes in
mRNA transcript levels. We demonstrated that the results
obtained with our PASSPORT-seq assay did reflect those
obtained with the traditional luciferase reporter assay set-up.
As described above, the PASSPORT-seq assay quantifies the
relative expression of luciferase mRNAs, whereas the luciferase
assay measures the luciferase enzyme activity. Thus, it is not
surprising that there may be differences in the magnitude of
effects between the different assays. For example, the effect
on the luciferase activity could be larger due to both the
degradation of the mRNA and the blockade of translation.
In contrast, the effect on the protein levels and activity
could be smaller due to delays from the time of changes
in mRNA levels until the changes in protein levels and
activities are observed. Typically, changes in mRNA expression
due to endogenous miRNA-mediated regulation are subtle
(<30%) (Baek et al., 2008; Bartel, 2009; Denzler et al., 2016).
Consequently one would expect relatively small effect sizes
of the variants, which was what was seen in many of these
variants. However, there are many examples demonstrating the
clinical impact of these types of variants (Bhattacharya et al.,
2014).
One of the key findings of these studies is the cell line-
specific function of mirSNPs. This is likely in part due to
the cell type specific variation in miRNA expression profiles
resulting in the effect of a mirSNP being evident in one cell
line and not in another (Landgraf et al., 2007; Ludwig et al.,
2016). We observed that the identity and number of functional
mirSNPs reproducibly varied across the different cell types.
This demonstrates one of the strengths of PASSPORT-seq in
that it can identify cell line-specific effects of mirSNPs. These
differences were validated using a second PASSPORT-seq run
that reproduced the cell line effect. Additionally, the cell line-
specific effect was also observed in the application of the assay
to test 111 mirSNPs in pharmacogenes. The tissue/cell specificity
of mirSNP function could also explain why the effects of mirSNPs
are not always consistent across studies. This further complicates
the bioinformatics predictions of the functional impact of the
mirSNPs. Thus, when using this assay, the cell line must be
carefully chosen to reflect the cell type of interest regarding the
central biological hypothesis of the study. Since studies have
shown that mirSNPs affect a wide variety of biological processes
such as cancer, neurodegenerative disorders, infectious diseases,
cardiovascular disease, and metabolic disorders (Bhattacharya
et al., 2014), the in vitro model for testing the mirSNPs is an
important consideration.
As with any in vitro assay, PASSPORT-seq has some
limitations. First, it detects only changes in mRNA, rather
than protein levels. miRNA- mRNA interactions are known to
cause mRNA destabilization, but can also lead to translational
repression (Lim et al., 2005; Bartel, 2009). Since this assay
does not detect changes in translation, it may underestimate
the functional impact of some of the mirSNPs. Second, the
variants could be affecting mRNA stability by mechanisms other
than by altering miRNA targeting. For example, it could be
altering RNA binding protein function that could alter the
mRNA stability. Although this would need additional validation
experiments to determine the mechanism of action, it would
still be of biological value. Last, like other studies using
the pISO plasmid, the miRNA binding site is tested in the
context of the luciferase mRNA, rather than the endogenous
mRNA.
In summary, the PASSPORT-seq assay is a powerful tool
that bridges bioinformatic predictions and high-throughput
mechanistic investigation of functional genetic variants that
affect miRNA–mRNA interactions. Future efforts will be
aimed toward further increasing the capacity of the assay
and identifying translational effects. This assay also has
the potential to be modified to be applicable to genetic
variants in other functional genomic regions such as
promoters and splice junctions. Collectively, these assays
will be key to elucidating the mechanisms underlying
the genetic contribution to the inter-individual phenotypic
variability.
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